Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
The Oncologist|April 24, 2022
Blood-Based Next-Generation Sequencing in Adrenocortical CarcinomaBassel Nazha, Tony Z Zhuang, Hiba I Dada, et al.
Oncology|June 19, 2018
Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I TrialsTaofeek K Owonikoko, Adeniyi K Busari, Sungjin Kim, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 17, 2017
Time-dependent effects of prognostic biomarkers of systemic inflammation in patients with metastatic renal cell carcinomaWayne B Harris, Chao Zhang, Yuan Liu, et al.
Cancer|January 5, 2024
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockadeEric J Miller, Tracy L Rose, Benjamin L Maughan, et al.
The Oncologist|September 19, 2025
Phase I study of palbociclib with cisplatin or carboplatin in the management of patients with advanced pancreatic cancerOlatunji B Alese, Robert Donald Harvey, Christina Wu, et al.
Frontiers in Health Services|March 25, 2024
Addressing disparities in cancer clinical trials: a roadmap to more equitable accrualJon A Hoin, Bradley C Carthon, Shantoria J Brown, et al.
The Oncologist|March 13, 2020
Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsDylan J Martini, Yuan Liu, Julie M Shabto, et al.
The Oncologist|November 25, 2022
Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsTony Z Zhuang, Deepak Ravindranathan, Yuan Liu, et al.
Journal of Immunotherapy and Precision Oncology|January 15, 2025
Real-World Outcomes in Patients with Advanced Penile Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Single Institution ExperienceTony Z Zhuang, Subir Goyal, Katherine B Case, et al.
The Prostate|January 29, 2026
Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809)Anna C Ferrari, Yu-Hui Chen, Ronald Rodríguez, et al.
Pageof 6